Why the study?
Immune checkpoint inhibitors and VEGFR inhibitors can cause cardiovascular events, raising concern that combination therapy could lead to MACE.
Does avelumab plus axitinib compared to sunitinib increase major adverse CV events in patients with advanced renal cell carcinoma, and what is the value of prospective cardiac monitoring?
Population
Patients with advanced renal cell carcinoma
Comparison
Avelumab plus axitinib vs sunitinib
Design
Phase III randomized trial with prospective serial cardiac monitoring
Authors
Loading...
Baseline troponin T elevation signals higher MACE risk with avelumab-axitinib; questions routine on-treatment LVEF monitoring in asymptomatic patients.
Does avelumab plus axitinib compared to sunitinib increase major adverse CV events in patients with advanced renal cell carcinoma, and what is the value of prospective cardiac monitoring?
In patients receiving avelumab plus axitinib for advanced renal cell carcinoma, high baseline troponin T levels may predict MACE, but routine on-treatment LVEF monitoring in asymptomatic patients has no clinical value.
Rini et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: